HR-7552-119
Referred to the Committee on Foreign Affairs, and in addition to the Committees on Financial Services, and Oversight and Government Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Barry Moore (R-AL)
What it does
This bill would establish a tiered, escalating sanctions regime targeting foreign governments whose officials, employees, or agents knowingly — or should have known they were — contributing to fentanyl production, distribution, or chemical/biological weapons programs that harm other countries. The President would be required to impose initial sanctions (blocking procurement from that country's chemical and biological sectors), then progressively stronger measures including cutting foreign assistance and ultimately prohibiting all financial transactions involving that country that fall under U.S. jurisdiction. The President could waive sanctions for up to five years for vital national security reasons, and must lift sanctions once the underlying conduct is addressed.
Who benefits
Americans harmed by fentanyl-related overdoses and their families. U.S. law enforcement and public health agencies seeking additional diplomatic leverage over foreign fentanyl supply chains. Domestic chemical and pharmaceutical manufacturers who compete with sanctioned foreign chemical sector firms. U.S. allies whose populations are also affected by fentanyl trafficking. Countries that are victims of chemical or biological weapons programs. Financial institutions that gain clearer legal guidance on prohibited transactions.
Who is hurt
Foreign governments and their state-linked chemical sector entities subject to sanctions, most directly China given the bill's title. U.S. businesses that import chemicals or goods from sanctioned countries' chemical and biological sectors, who may face supply chain disruptions or higher input costs. Industries reliant on Chinese-origin chemical precursors, including U.S. pharmaceutical and agricultural manufacturers. U.S. exporters who may face retaliatory trade measures from sanctioned countries. Diplomatic and national security officials who may lose flexibility in managing foreign relationships. Foreign nationals employed by sanctioned entities.
Supporters argue
Supporters argue that China-linked chemical companies have been documented by the DEA and Treasury Department as knowingly supplying fentanyl precursors that fuel an overdose crisis killing over 70,000 Americans annually. They contend that existing voluntary diplomatic channels have failed to stop the flow of precursor chemicals, and that mandatory, escalating sanctions create enforceable consequences that give foreign governments a clear incentive to act — something discretionary executive tools have not achieved.
Opponents argue
Opponents argue that mandatory sanctions remove the President's flexibility to use economic pressure as part of broader diplomatic negotiations, potentially undermining leverage on higher-priority national security issues with major powers like China. They contend that fentanyl precursor supply chains are diffuse and adaptive, meaning sanctions on state-linked entities may simply shift production to non-state actors without reducing the overall drug supply, while risking economic retaliation that harms U.S. industries and workers.